Ascariasis

Summary

Ascariasis (MONDO:0005654) is a disease and 7 clinical trials. Top therapeutic interventions include albendazole, moxidectin, and ivermectin. A subtype of Ascaridida infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ascariasis
Mondo ID	MONDO:0005654
EFO	EFO:0007154
MeSH	D001196
DOID	DOID:456
ICD-10-CM	B77
ICD-11	17842540
NCIT	C128392
SNOMED CT	2435008
UMLS	C0003950
MedGen	2087
GARD	0027724
Is cancer (heuristic)	no

Also known as: Ascaris lumbricoides caused disease or disorder · Ascaris lumbricoides disease or disorder · Ascaris lumbricoides infectious disease

Disease family

This is a subtype of Ascaridida infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › Nematoda infectious disease › Rhabditida infectious disease › Ascaridida infectious disease › ascariasis

Related subtypes (5): baylisascariasis, ascaridiasis, toxascariasis, toxocariasis, anisakiasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2
Not specified	2
PHASE4	1
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00659997	PHASE4	COMPLETED	Efficacy Albendazole and Levamisole Against STH on Unguja
NCT04700423	PHASE2/PHASE3	COMPLETED	Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
NCT04726969	PHASE3	COMPLETED	Efficacy and Safety of MOX/ALB Co-administration
NCT06188715	PHASE3	COMPLETED	Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
NCT06184399	PHASE2	COMPLETED	Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
NCT00207753	Not specified	COMPLETED	Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections
NCT01658774	Not specified	COMPLETED	Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALBENDAZOLE	4	3
MOXIDECTIN	4	2
IVERMECTIN	4	1
LEVAMISOLE	4	1
DEXAMISOLE	2	1
CHEMBL4782609	0	2
CHEMBL5280985	0	2
CHEMBL263291	0	1
CHEMBL4082099	0	1
CHEMBL4788951	0	1